There are three parts to the business as you know.
However the Admedus sales business is the head of them and the only one which we own 100%. The other 2 are sorta brake away and in there own right can make us money overtime.
If you look at Morgans reports they tell you that it's the Admedus sales business is where the sales from CardioCel will be reported and if all goes well so will the Vaccines too.
Both Coridon and celxcel are researchers with no means to sell products other than through the sale business ATM, however that could change, with a licensing deal if that is part of the licensing deal that they seek to have, as part of the terms.
Celxcel with one product approved and 6/7 to go with research and time
Coridon 4 to 5 Vaccines to research and one due to report full phase 1 results soon all in the hope of getting to the market
It is Admedus medical sales business that will grow with sales albeit on the back of the others 2 companies that we own the bulk of and mainly CardioCel which is on the market now.
And I wouldn't right off getting more products to sell or more contracts. They get new contracts all the time but most are small and not big enough to tell the market.
- Forums
- ASX - By Stock
- AVR
- medical equipment business forward plans
medical equipment business forward plans, page-3
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$13.72 |
Change
0.520(3.94%) |
Mkt cap ! $281.1M |
Open | High | Low | Value | Volume |
$13.08 | $13.84 | $12.84 | $71.60K | 5.438K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 517 | $13.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.72 | 112 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 517 | 13.240 |
2 | 64 | 13.230 |
1 | 59 | 13.210 |
1 | 88 | 13.200 |
1 | 200 | 13.020 |
Price($) | Vol. | No. |
---|---|---|
13.720 | 144 | 2 |
13.770 | 63 | 1 |
13.810 | 2 | 2 |
13.850 | 60 | 1 |
13.860 | 41 | 1 |
Last trade - 13.29pm 29/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |